ROS1ders-Primary-White-Green.png
  • For Patients

    • Guide for Patients
    • Treating ROS1 (For Patients)
    • Coping with Side Effects
    • Clinical Trials (For Patients)
    • Find a ROS1 Physician
    • Managing Finances
    • Connect with Our Community
  • For Healthcare Professionals

    • Treating ROS1 (for HCPs)
    • ROS1 Clinical Trials
  • Our Research

    • Global ROS1 Initiative
    • Cancer Model Project
    • Real World Data Project
  • Blog

  • About Us

    • About The ROS1ders
    • Team
    • Publications
    • In The News
    • Contact
    • Donate
  • More

    Use tab to navigate through the menu items.
    ROS1ders-Icons-White-Community.png
    Donate

    ROS1ders Blog

    Articles and Resources for ROS1+ Patients, Families, and Health Professionals.

    • All Posts
    • Advocacy
    • Biomarker Testing
    • Events
    • Patient-Driven Research
    • Cancer Progression
    • Research
    • Resources
    • Survivorship
    • Treatments and Trials
    • Fundraising
    • ROS1ders Stories
    Search
    Confused about 1st and 2nd line drugs? Here’s a guide!
    Renee Parker
    • Dec 30, 2019
    • 2 min

    Confused about 1st and 2nd line drugs? Here’s a guide!

    The ROS1ders Interview Dr. Ross Camidge
    Janet Freeman-Daily
    • May 16, 2019
    • 1 min

    The ROS1ders Interview Dr. Ross Camidge

    pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC
    Janet Freeman-Daily
    • May 5, 2019
    • 1 min

    pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

    ROS1 News From Europe
    Bärbel Söhlke
    • Apr 16, 2019
    • 2 min

    ROS1 News From Europe

    Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors
    Janet Freeman-Daily
    • Feb 19, 2019
    • 1 min

    Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

    Thinking about a “drug vacation” from crizotinib? Read this first!
    Janet Freeman-Daily
    • Jan 17, 2019
    • 3 min

    Thinking about a “drug vacation” from crizotinib? Read this first!

    Crizotinib approved for ROS1 in Australia
    Janet Freeman-Daily
    • Dec 31, 2018
    • 1 min

    Crizotinib approved for ROS1 in Australia

    NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC
    Janet Freeman-Daily
    • Dec 14, 2018
    • 1 min

    NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

    U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC
    Janet Freeman-Daily
    • Nov 5, 2018
    • 1 min

    U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

    Crizotinib may be effective again after chemo
    Janet Freeman-Daily
    • Aug 27, 2018
    • 1 min

    Crizotinib may be effective again after chemo

    TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP
    Janet Freeman-Daily
    • Jun 15, 2018
    • 1 min

    TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP

    Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)
    Joyce Hoelting
    • Jan 5, 2017
    • 4 min

    Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)

    Top of Page
    ROS1ders-Primary-White-Green.png

    The ROS1ders, Inc.
    1721 Eastern Avenue, Suite 19
    Sacramento, CA  95864
    +1 (916) 382-8544
    info@theros1ders.org


    A 501(c)(3) nonprofit corporation
    EIN 83-4490547

    Disclosures

    This website is not intended to, and does not provide, medical advice, professional diagnosis, opinion, treatment, or services. Medical information provided on this site is for informational and educational purposes only. After reading content from this website, you are encouraged to review the information carefully with your physician.

    Connect with Our Community

    Contact Us

    Join Private Facebook Group

    • Facebook
    • Twitter
    • YouTube
    • LinkedIn
    • Instagram

    Email Webmaster